| 000 | 01836cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031003.0 | ||
| 008 | 140520s2013 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.04.Ph.D.2013.Yo.P | ||
| 100 | 0 | _aYousery Wasef Kamel | |
| 245 | 1 | 0 |
_aPossible prognostic significance of plasma urokinase plasminogen activator in breast cancer / _cYousery Wasef Kamel ; Supervised Zekry Khalid Zekry , Nadia I. Zakhary , Rabab Mohamed Gaafar |
| 246 | 1 | 5 | _aالمغزى المبشر الممكن لمنشط بلازمينوجين يوروكينيز فى البلازما فى سرطان الثدى |
| 260 |
_aCairo : _bYousery Wasef Kamel , _c2013 |
||
| 300 |
_a163 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) | ||
| 520 | _aBreast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death in female's worldwide accounting for 23% (1.38 million ) of the total new cancer cases and 14% (458,400) of the total cancer deaths . Urokinase plasminogen activator (uPA) is involved in regulating BC invasion and metastasis explained by its ability to facilitate ECM degradation cell proliferation angiogenesis migration and adhesion | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aMetastatic breast cancer | |
| 653 | 4 | _aNon- metastatic breast cancer | |
| 653 | 4 | _aUrokiase plasminogen activator | |
| 700 | 0 |
_aNadia I. Zakhary , _eSupervisor |
|
| 700 | 0 |
_aRabab Mohamed Gaafar , _eSupervisor |
|
| 700 | 0 |
_aZekry Khalid Zekry , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c46120 _d46120 |
||